Skip to main content
main-content

Type 2 diabetes

Highlights

04-24-2019 | Type 2 diabetes | Feature | Article

Young-onset type 2 diabetes: A different process?

Escalating obesity prevalence and severity has led to type 2 diabetes being diagnosed in ever-younger people, including children. medwireNews rounds up the accumulating evidence suggesting a particularly severe diabetes course in these young people.

04-15-2019 | Nephropathy | Highlight | News

Canagliflozin may offer renal protection in people with type 2 diabetes and CKD

Findings from the CREDENCE trial indicate that the SGLT2 inhibitor canagliflozin reduces the risk for renal failure and cardiovascular disease among individuals with type 2 diabetes and albuminuric chronic kidney disease.

03-26-2019 | Semaglutide | Highlight | News

PIONEER 3: Oral semaglutide proves worth against sitagliptin

Oral semaglutide offers greater efficacy for glucose control and weight loss when compared with sitagliptin for people with type 2 diabetes, although with more adverse events at the highest dose, show the PIONEER 3 findings.

03-18-2019 | Dapagliflozin | Highlight | News

DECLARE analyses show dapagliflozin benefits for reduced ejection fraction, prior MI subgroups

Further analysis of the DECLARE-TIMI 58 trial shows dapagliflozin to be of particular benefit for patients who have previous myocardial infarction or heart failure with reduced ejection fraction.

03-12-2019 | Medications | DUKPC 2019 | News

Adding second diabetes medication better than switching in face of poor response

Adding an additional glucose-lowering medication is better than switching to a different one in people with type 2 diabetes, even if the original seemed to have little or no effect, shows an analysis from the MASTERMIND consortium.

03-05-2019 | Physical activity | Highlight | News

Behavioral intervention has durable physical activity effect in type 2 diabetes

A behavioral intervention has lasting effects on physical activity levels, fitness, and vascular risk in people with type 2 diabetes, show the 3-year results of the randomized Italian Diabetes and Exercise Study 2.

02-25-2019 | Devices and technology | Highlight | News

d-Nav system helps people with type 2 diabetes optimize insulin doses

The d-Nav system, which calculates insulin dose adjustments according to glucose levels, can help people with type 2 diabetes achieve larger reductions in glycated hemoglobin levels than with healthcare professional support alone, shows a randomized trial in The Lancet.

01-29-2019 | Cardiovascular outcomes | Highlight | News

Gap in cardiovascular risk not closing for people with type 2 diabetes

The incidence of coronary heart disease has declined in recent years but people with type 2 diabetes continue to have a significantly greater risk than those without, Scottish data show.

01-17-2019 | Glucokinase activators | Highlight | News

Hepatic glucokinase activation may improve glycemic control in type 2 diabetes

The hepatoselective glucokinase activator TTP399 reduces glycated hemoglobin levels without increasing the risk for hypoglycemia among patients with type 2 diabetes, suggest findings from the phase IIb AGATA trial.

01-02-2019 | Canagliflozin | medwireNews | News

No fracture risk found with canagliflozin in real-world data

Research based on insurance claims data indicates that new users of the sodium-glucose cotransporter-2 inhibitor canagliflozin are no more likely to experience a fracture than new users of glucagon-like peptide-1 receptor agonists.

12-19-2018 | Insulin degludec | Highlight | News

Real-world data show benefits of insulin degludec vs glargine in type 2 diabetes

Insulin-naive adults with type 2 diabetes derive greater benefit from treatment with insulin degludec than from insulin glargine 300 units/mL, results from the US clinical practice-based CONFIRM study show.

12-14-2018 | Risk factors | Feature | Article

Sleep duration: Waking up to a major metabolic risk factor

The effect of sleep duration on glucose regulation and cardiometabolic risk is becoming an increasingly high-profile issue. medwireNews takes a look at the latest evidence, which shows the gravity of the problem but also offers some solutions.

12-07-2018 | DPP-4 inhibitors | medwireNews | News

Possible bile duct cancer risk with incretin-based medications

Data from clinical practice suggest the possibility of an increased relative risk for cholangiocarcinoma among patients taking incretin-based antidiabetes medications, although the absolute risk remains small.

12-03-2018 | Liraglutide (T2DM) | medwireNews | News

Older type 2 diabetes patients may derive greatest liraglutide benefits

The LEADER investigators report that treatment with the glucagon-like peptide-1 receptor agonist liraglutide may be of particular benefit in the oldest patients with type 2 diabetes.

11-21-2018 | Risk factors | Highlight | News

Shift work plus unhealthy lifestyle add up to high diabetes risk

The total diabetes risk associated with the combination of rotating shift work and an unhealthy lifestyle is greater than that of the two added together, shows an analysis of the Nurses’ Health Studies.

11-20-2018 | Insulin | Highlight | News

Research predicts ‘highly inadequate’ insulin access in coming years

A modeling study predicts a greater than 20% increased need for insulin to treat patients with type 2 diabetes over the next 22 years, with implications for medication access.

11-10-2018 | Dapagliflozin | Highlight | News

DECLARE-TIMI 58 supports CV benefits of SGLT2 inhibitor class

The results of the DECLARE-TIMI 58 trial show a broadly positive effect of dapagliflozin on cardiovascular outcomes, especially heart failure, in patients with type 2 diabetes.

11-06-2018 | Cardiovascular outcomes | Highlight | News

Type 2 diabetes, polyvascular disease combine to increase cardiovascular risk

Type 2 diabetes and polyvascular disease are additive risk factors for cardiovascular events in patients with acute coronary syndromes, a secondary analysis of the IMPROVE-IT trial suggests.

10-30-2018 | Glycemic control | Highlight | News

Improved oral health could help glycemic control in type 2 diabetes

A year of intensive periodontal treatment is associated with a significant reduction in glycated hemoglobin levels in patients with type 2 diabetes and moderate-to-severe periodontitis, UK researchers report.

10-16-2018 | Metabolic surgery | medwireNews | News

Marked reduction in vascular events in diabetes patients after bariatric surgery

An observational study published in JAMA demonstrates a substantial reduction in the risk for hard cardiovascular endpoints in obese patients with type 2 diabetes who have undergone bariatric surgery.

image credits